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Abstract. We investigated the role of public funding in cardiovascular device innovation
across 31 countries in Europe. We rely on the knowledge production function (KPF)
framework that establishes the knowledge output of a region as a function of innovatory
effort and other characteristics of that region. In a cross-sectional analysis, we investigated
regional variation in knowledge production by the number of publications in cardiovascular
device research obtained from the bibliometric data of the world’s largest biomedical
library, the US National Library of Medicine, 2014–2017. We mapped these publications
to product categories of medical devices approved for cardiovascular diseases by the US
Food and Drug Administration. Considering spatial correlation across regions of Europe
in our estimates of the KPF, we investigated the impact of two types of public funding
mechanisms: the volume of European Union (EU) Framework Programme (FP) 7 funding
received by the innovating regions and that of its successor the EU Horizon 2020 funding.
We obtained 123,487 cardiovascular device-related publications distributed across 1,051
(75% of total) regions (NUTS-3 level). Receiving public funding strongly contributes to a
region’s knowledge output. The estimated elasticities of innovatory effort by FP7 range
between 0.36 and 0.40 while the estimated elasticities of Horizon 2020 range between
0.13 and 0.17. Estimated elasticities remain robust after controlling for country level
fixed effects. When accounting for additional inputs to the KPF by private funding and
health system related factors, the elasticity estimates for FP 7 and Horizon 2020 reduced,
but remained significant. We documented spillover from neighboring regions, albeit at
small scale. Our results conclude that innovatory efforts in the form of public research
investments are effective for promoting innovation in the medical device industry at the
regional level.
JEL classification: R11, R12, O32, O52
Key words: Innovation, Regional Innovation System, Medical Technology, Cardiovas-
cular Devices, Innovatory Spillover, Spatial Spillover
1 Introduction
In a learning economy, innovation is recognized as new knowledge resulting from user-
producer interaction. In the medical device industry, knowledge generation has led to
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a better clinical understanding of diseases, resulting in improved medical procedures in
addition to technological advancements. For example, the evolution of the left ventricular
assist device began with advances in understanding heart failure, leading to improvements
in the medical procedures, further improving the design of the device (Morlacchi, Nelson
2011). As in other industries, such user-producer interaction in the medical device
industry may tend to cluster innovation systems that, in turn, accelerates knowledge
production (Cooke et al. 1997, Asheim, Isaksen 1997, Asheim, Coenen 2005).
In this study, we analyzed regional innovation systems (RIS) of cardiovascular medical
devices by accounting for the spatial distribution of knowledge and quantifying the role
of public funding as an innovatory effort in a knowledge production function (KPF). The
medical device industry typically ranks high in terms of its patent share in Europe – 7.7%
of all patents to the European Patent Office are filed for medical devices (MedTech 2020a).
The European market is the second largest in the global medical device industry (27%
of revenues), with a trade surplus of about 11.7 billion Euro in 2018. However, industry
activities are spread unevenly across different clusters in terms of market, employment,
and trade shares. Of the roughly 32,000 companies active in the industry, 95% are small
and medium-sized enterprises (SMEs) employing more than 730,000 employees across
Europe. A geographical variation exists in terms of implant/usage rates of devices at
both regional and country levels in Europe (Tarricone et al. 2017).
New medical devices develop from the interplay of scientific advancements, learning
in medical practice, and technological development where physicians are often key con-
tributors to device development as entrepreneurs (Morlacchi, Nelson 2011, Smith, Sfekas
2013). When interactive involvement of physicians is considered in advancing medical
device innovation, the question remains how and which investments in research and
development (R&D) contribute. The SMEs and physicians in Europe have depended
on public and private investments, of which public funding contributes a substantial
proportion (MedTech 2020b). Targeted scientific research funding and coordination by
research institutes have been identified as the strongest opportunities (Maresova et al.
2015). While the distribution of public research funding on cardiovascular research
is heterogeneous (Pries et al. 2018), the effectiveness of public funding from national
and supranational levels such as the European Union’s Framework 7 and Horizon 2020
programs on knowledge output is unclear. Previous evidence, irrespective of the industry,
demonstrates the effectiveness of innovatory efforts by measuring R&D investments,
human capital, and intermediary scientific institutes on the knowledge output of patents
(Moreno et al. 2005, Marrocu et al. 2013, Fritsch, Franke 2004). Understanding what
leads to new knowledge and subsequent innovation in the medical device industry is
important because the patients with access to highly innovative clinicians and firms in
their region will likely benefit from these innovatory efforts. For example, significant
regional level differences in use, along with hospital mortality, were documented in the
case of transcatheter aortic valve implantation by region in the United States (Gupta
et al. 2017).
This study aimed to investigate the role of public funding in cardiovascular device
innovation. We relied on the KPF framework that establishes regional knowledge output
as a function of innovatory effort that we examined by public funding. We investigated
regional variation in knowledge production by the number of publications in cadiovascu-
lar device research from bibliometric data obtained from the world’s largest biomedical
library, the US National Library of Medicine (NLM). We evaluated the effectiveness of
receiving public funding mainly through the European Union (EU)’s funding programs
on regional level knowledge production in Europe (31 countries consisting of EU-27,
the UK, Switzerland, Iceland, and Norway). We further accounted for variation in
private funding by capturing sponsorship received by randomized controlled trials in
our publication data. In addition, we performed subgroup analyses in four countries to
capture additional healthcare system level variation. We expected to find that receiving
public research funding positively influences the regional knowledge output for innovation
in cardiovascular devices.
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2 Background
2.1 Innovation pathways in cardiovascular device research and development and health
outcomes
Our study setting emphasizes cardiovascular devices because, within the medical device
industry, many significant advancements have been made to improve the treatment and
diagnosis of cardiovascular diseases. These include various diseases linked to heart and
blood vessels, such as heart failure, stroke, arrhythmia, heart disease, and heart valve
problems. Besides cancer research, advancements in cardiovascular research contributed
to an increase in life expectancy of around 3.73 years in the US from 1950 to 2000
(Murphy, Topel 2006). Many cardiovascular devices are products of this research contri-
buting to health gains; several important cardiovascular device innovations – such as elec-
trocardiogram, cardiac catheterization, computed tomography, and magnetic resonance
– were products of Noble Prize-winning research (Mesquita et al. 2015).
Our focus is on the innovation stage that lies beyond the invention of a medical
device, since they undergo incremental innovation in multiple tests and validation stages
before market launch and commercialization, but also post-marketing approval phases
(Dziallas, Blind 2019, Tarricone et al. 2017). In this way, the innovation activity of a
device is observed during the “design-build-test-redesign” cycle instead of the preliminary
prototype stage. It often takes place in collaboration with physicians who experience
unmet needs in their clinical practice. Physicians also take part in clinical studies where
the safety and efficacy of a new medical device need to be demonstrated before adopting it
into clinical practice (Kaplan et al. 2004, EMA 2019). For example, the coronary artery
stents, invented by physicians and researchers, became widespread only after various
clinical trials demonstrated them to be safe and effective (Xu et al. 2012, Mckavanagh
et al. 2018). Moreover, user-producer interaction in the post-market approval phase is
crucial (Ciani et al. 2016). In this phase, technology scope is often refined with physicians’
feedback long after the initial device-design was invented. For example, the device
scope of cardiac resynchronization therapy widened because clinical studies revealed
its applications in new and diverse patient groups (Boriani et al. 2018). Such user-
oriented and process-oriented innovations are often recorded as results of clinical studies
and scientific publications. In terms of financing, such stages of testing, validation, and
redesign involve academic centers that rely on various funding sources. Public funding
of individual inventors and clinicians is acknowledged to foster innovation in the medical
device domain (Xu et al. 2012).
Analyzing innovative activity in cardiovascular research not only has implications
for knowledge production and subsequent innovation but also for cardiovascular disease-
related health outcomes. More than 1.8 million deaths were attributed to cardiovascular
diseases in 2016 in Europe alone (Eurostat 2016, WHO 2017). Cardiovascular morbidity
and mortality are highly variable across regions, even within the same country. Patient’s
access to new devices remains higher in areas where adopting new devices is more likely.
The role of the supply side and related physician behavior is emphasized in explaining
regional variation in health outcomes in the health-economic literature (Bech et al. 2009,
Cutler et al. 2019). Therefore, patients in regions with higher innovative activity have
higher health benefits from the early use of innovation. As the financial burden of
cardiovascular diseases is high, ¿196 billion in 2013 in Europe (Komajda et al. 2013), the
potential of efficiency gains from knowledge production translating to the bedside is high.
Although we will focus on knowledge production occurring at the incremental innovation
phases (testing, validating, and post-marketing feedback), our results may have wider
implications on the regional variation in the productivity of health care systems.
2.2 Regional Innovation Systems for Research and Development
Innovation systems develop via interventions received at regional levels and are typically
analyzed by regional-level R&D activities (Buesa et al. 2010, Moreno et al. 2005, Cooke
et al. 1997). Hence, we assume that cardiovascular device innovations emerge from
regional R&D activities involving vertically interconnected actors, such as medical device
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manufacturers, physicians, and academia. By considering the availability of R&D invest-
ments, particularly of public funding mechanisms at the regional level, we can analyze if
such opportunities promote the innovative capacity of a region.
Analyzing this capacity requires accounting for the spillover effects by innovative
activities in neighboring regions as previous evidence suggests it influences the knowledge
output of a region (Moreno et al. 2005, Gumbau-Albert, Maudos 2009, Marrocu et al.
2013, Bottazzi, Peri 2003). Out of four types of proximities explored in the literature
that consider possible spillovers, we focus on geographical proximity (Usai et al. 2015).
Previous evidence suggests that technological proximity can be even more impactful
than geographical proximity when considering innovatory effort across many industrial
sectors (Marrocu et al. 2013). However, we focus on geographical proximity, by analyzing
regional variation in knowledge production, within the same technological field, i.e.,
cardiovascular devices. Social and organizational proximities are known to be less im-
pactful when performing cross-regional comparisons (Marrocu et al. 2013).
2.3 Knowledge Production Function to Investigate the Innovatory Effort by Public
Research Investments
To understand how public funding influences knowledge production regarding cardio-
vascular devices, we based our analysis on the knowledge production function (KPF)
framework developed by Griliches and Jaffe (Jaffe 1989, Grillitsch, Asheim 2018).
Kr = f(Rr, Zr) (1)
Kr refers to knowledge production in terms of innovative output in region r that is a
function of two inputs. Rr is the innovatory effort of region r based on the endogenous
growth model, which implies that production output is a function of endogenous (regional)
factors (Furman et al. 2002). Zr are additional regional indicators of this same region,
such as the economic and financial capacity.
To measure knowledge production Kr, we rely on a bibliometric measure of innovation
by capturing the number of publications in the field of cardiovascular devices. Although
literature-based innovation measures were initially preferred as direct measures, most
previous approaches have captured knowledge production by either R&D inputs or
patents (Acs et al. 2002, Acs, Audretsch 1993, Coombs et al. 1996). R&D investments
represent allocated investments but not necessarily innovation and must be considered
inputs instead of outputs (Pavitt et al. 1987). Patents reflect the state of the invention
but do not necessarily reflect the innovation it perpetuates as it continues to develop
and diffuse. Patents, also, cannot capture innovation arising from daily practices that
are often not patented (Pakes, Griliches 1980, Acs, Audretsch 1993). Since innovative
activities of cardiovascular devices involve physicians in both pre- and post-launch phases,
we rely on publications to capture the innovative activities most likely expressed in terms
of clinical studies, scientific guidelines, or case reports. It is reflected by the globally
increased number of publications in cardiovascular research, with Europe having outpaced
the US and China in the 1990s and 2000s (Gal et al. 2017).
We considered innovatory effort Rr as the regional level research investments as
funding received by the EU Framework 7 and EU Horizon 2020 programs. Previous
studies have empirically identified positive effects of financing mechanisms (mostly, as the
share of internal R&D) or human capital on the knowledge output of regions (Gumbau-
Albert, Maudos 2009, Charlot et al. 2015, Tappeiner et al. 2008). Public funding is an
important type of investment in research because it is pre-investment, similar to venture
capital investment, in which future outcomes are yet unclear. An advantage of using
public funding by EU programs is that it can be traced to the regions receiving it. We
also account for variation in private investments by the number of clinical trials receiving
sponsorship from private companies in our empirical approach.
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3 Data and Methods
To empirically analyze the impact of research investments on knowledge output, we
composed a cross-sectional data set of innovation activity in the years 2014–2017 by
linking multiple data sources. Our investigation covered 27 EU member countries as
of September 2020 plus the UK, Switzerland, Iceland, and Norway, summing up to
a list of 31 countries1. In the final data set, all the data was uniquely assigned and
aggregated to the level of 1,394 regions defined by NUTS-3. We then implemented
an empirical strategy that accounts for potential confounding on the effects of funding
mechanisms on knowledge output by considering additional regional characteristics and
spatial dependency across neighboring regions as additional inputs to the knowledge
production function.
3.1 Data Sources
To capture variations in knowledge output measured by publication activity due to
investments in research and regional environment according to their corresponding regions,
we extracted data from seven different sources [Supplement 1 – Source Data]. We
collected bibliometric data from the US NLM MEDLINE/PubMed baseline database as
the primary data source. It contains 26 million and 30 million publication records from
MEDLINE and PubMed, respectively (Amelung 2017). We relied on the 2018 version of
the baseline database that provides 4,374,797 citation records that we obtained via bulk
download (NLM 2020a,c).
Although the US NLM is from the US, it is the prime source for biomedical research
globally. Journals not included in the PubMed/Medline possibly do not meet the quality
standards set by the US NLM (NLM 2021). Our captured publications, therefore, ensure
that the knowledge generated is incremental. We further ensure that the coverage of
Europe-origin journals is high, given that Europe-based authors may prefer to publish
in them. Using the SCImago Journal & Country Rank database that lists 173 journals
in cardiology and cardiovascular medicine with publishing offices in EU-28 countries, we
found 141 journals (i.e., 81%) included in the PubMed/Medline baseline database as of
2021. The other 19% may not have met PubMed/Medline’s quality standards.
To select relevant records from MEDLINE/PubMed, we used NLM’s thesaurus clas-
sification of Medical Subject Headings (MeSH). The MeSH terms are NLM’s in-house
developed keywords for cataloging each publication depending on its subject matter
(NLM 2019a). MeSH terms are assigned to each publication by a team of indexers
who systematically scan the title, abstract, and publication. The MeSH classification is
provided by a hierarchical tree structure containing 16 main branches, including diseases,
drugs, therapeutic equipment, and processes, and each branch contains hierarchical sub-
branches2 In addition to its definition, each MeSH is described by a “DescriptorName”
for one word/phrase description and is accompanied by “DescriptorUI”, a unique ID
number for that particular MeSH (NLM 2019b). Per publication, multiple MeSH terms
may be assigned (NLM 2020b). We relied on the 2019 version of the MeSH tree.
Third, we used the U.S. Food and Drug Administration’s (FDA) Product Code
Classification Database to classify cardiovascular devices (FDA 2018). Most importantly,
this database provides generic definitions of a set of approved medical devices by disease
indication and the typical classification of medical devices by their risk. Fourth, we
collected gross domestic product (GDP) per region for the years of 2014 to 2017 from
Eurostat (Eurostat 2020) and national statistical offices in Switzerland (BFS 2019) and
Iceland (Statistics Iceland 2019). Fifth, we obtained data on research funding received
under EU Framework 7 and Horizon 2020 program at regional level as provided by the
official online dashboard of the European Commission (European Commission 2020b).
1Liechtenstein was excluded from the dataset as no publications were recorded on cardiovascular
devices.
2For example, the main branch “Analytical, Diagnostic and Therapeutic Techniques, and
Equipment” includes “Surgical Procedures, Operative” as a sub-branch containing additional sub-
branches such as “Cardiovascular Surgical Procedures” that has “Heart Valve Prosthesis Implantation”
as a sub-branch that in turn has “Transcatheter Aortic Valve Replacement.”
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Sixth, we collected data about funding status of registered clinical trials reported in the
extracted publications from the database provided by ClinicalTrials.gov (2021). Seventh,
we collected additional characteristics of the region to account for health system related
factors in a subset of four countries, relying on a publicly available previous data collected
for these variables (Rabbe et al. 2021).
3.2 Classification of Publications of Cardiovascular Devices
We developed a programming algorithm to extract all publications from MEDLINE/Pub-
Med that cover medical devices for cardiovascular diseases [Supplement 2 – Additional
External Variables] [Supplement 3 – Program Code for Data Extraction and Preparation].
First, based on the MeSH tree, we classified publications as to whether they refer to
medical devices in general. Second, we restricted the sample to publications with those
MeSH terms for which we could attribute an approved medical device definition for a
cardiovascular specialty by the U.S. FDA. Although our study focused on Europe, we
relied on the classification of medical devices provided by the FDA because the recently
published European medical device nomenclature was under development at the time of
data-collection (European Commission 2020a).
To focus on publications about medical devices, using the MeSH tree, we included all
MeSH terms that cover analytical, diagnostic, and therapeutic techniques and equipment
[Supplement 4 – Auxiliary Data Created]. Specifically, we selected all the MeSH terms
of the sub-branches E01 (diagnosis), E02 (therapeutics), E04 (surgical procedures, ope-
rative), E06 (dentistry), and E07 (equipment and supplies), with 2,178 unique MeSH
terms in total.
To retain publications on medical devices explicitly for use in cardiovascular disease,
as a second step, we mapped the identified MeSH terms with cardiovascular devices
authorized by the U.S. FDA’s Product Code Classification Database (FDA 2018). In this
way, we ensured that the selected publications are linked to the FDA approved products
to maintain our focus on those that succeeded the approval process (Stern 2017). The
U.S. FDA medical device classification is based on risks posed by the devices on patients,
I being the lowest and III being the highest risk. In the Product Code Classification
Database, we selected all product definitions attributed to cardiovascular disease (medical
specialty “CV”). To focus on devices that are likely part of cardiovascular interventions
and avoid devices that mostly contain accessories to support interventions, we excluded
class I devices, which includes devices such as forceps and scissors, for example. We
included all 276 devices with moderate (class II, for example, cardiovascular blood flow
meter) and greatest risk (class III, for example, pacemaker/cardiac resynchronization
therapy) to patients (FDA 2017). The mapping exercise left us with 86 MeSH terms
[Supplement 4 – Auxiliary Data Created].
3.3 Assigning Publication Geolocations to Identify Regional Innovation Systems and
Knowledge Output
In total, we extracted data on 123,487 publications that we could assign to at least one
MeSH term relating to a cardiovascular device and to a geocode in Europe [Supplement
4 – Auxiliary Data Created]. To obtain the geographical distribution of the publications
of cardiovascular devices, we used the publicly available tool MapAffil to assign geocodes
(latitudes and longitudes) to each publication based on the authors’ affiliations (Torvik
2015). MapAffil is capable of correctly identifying 97.7% of the geolocation of a city
reported in the author’s affiliation variable provided by PubMed.
We restricted our analysis to publications published between 2014 and 2017 because
MEDLINE/PubMed’s indexing method started in 2014 to include information about
affiliations of multiple authors (NLM 2019b). We assumed that not accounting for
authors and their location beyond the first authors would heavily underestimate regional
contribution to the knowledge output. Medical device research is often performed in
networks of authors from different locations. In 2012, 40% of studies reported authors
from two or more countries (Gal et al. 2017). Based on the assigned geocodes, we
aggregated publications by regional level.
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To identify distinguished regions in the RIS of knowledge production of cardiovascular
devices, we relied on the geographical classification of regions defined by the Nomenclature
of Territorial Units for Statistics (NUTS), provided by Eurostat and the Organisation for
Economic Co-operation and Development (OECD) (Damanpour, Schneider 2009, OECD
2005). NUTS is a hierarchical geographical classification based on regional administrative
structures of countries and territories to perform socio-economic and statistical analysis.
Across all analyses, we used the 2016 version of the NUTS classification at the lowest level
3 as it refers to small regions for diagnosis of specific questions (Damanpour, Schneider
2009).
We distributed the geocodes of multiple affiliations of the same publication by equal
weight. For example, a publication with three authors referring to geolocations in
Milan, Munich, and Zurich was assigned three sets of geocodes corresponding to each of
these cities. If the publication included authors from outside Europe, we discarded the
affiliations from outside Europe to focus on innovation output located in Europe.
Data extraction was performed using SAS Enterprise Guide 9.4 (SAS Institute, Cary,
NC, USA). Statistical analysis was performed using R, version 4.0.2. All program codes
to extract and analyze all data sources and the data set for analysis are provided via the
Open Science Framework (OSF) repository.
3.4 Empirical Knowledge Production Function Model
The aim of our empirical strategy was to quantify the effect of research investments on
knowledge production measured by the number of publications assigned to one region,
accounting for potential confounding of other characteristics of the region as a secondary
input to knowledge production, and spatial dependency across regions. Considering the
specification of the KPF as stated by equation (1), we specified the following linear
regression model:
Kr = β̂1Xr + β̂2Zr + ϵr (2)
Kr refers to knowledge output (number of publications) of region r. Xr is our variable
of interest and captures innovatory effort of region r. Zr represents characteristics of
the region r itself that are reflected by suitable regional indicators. In our case, we
captured economic performance by considering the GDP of that region. ϵr captures the
error term. For all input and output variables, we provided specifications per capita by
dividing absolute values by the number of inhabitants in the region. The estimate of β̂1
captures the effectiveness of innovatory effort by two types of measures. Our primary
measure of innovatory effort is the monetary volume of funding received in the region
via the 7th EU framework programme (FP7). It was rolled out from 2007 to 2013
as part of European Commission’s research and innovation funding promotion to boost
economic growth in the European Union. The program offers financial aid to EU member
countries and a list of associated countries, including all countries in our analysis, and,
subsequently, research activities taking place in those countries eligible for it (European
Commission 2020c). It is the largest framework program for promoting research and
innovation across Europe. Controlling for other factors of the region Zr, we hypothesize
that innovatory effort made through FP7 causes knowledge production between 2014
and 2017 to increase. In addition, we include a separate variable for its successor EU
Horizon 2020, spanning from 2014 to 2020 (European Commission 2020d). That way,
we account for lags of innovatory effort and hypothesize that higher current innovatory
effort is associated with higher levels of knowledge production. In addition, we accounted
for country fixed effects to compare estimates with and without heterogeneity that may
persist due to first and second nature advantages between national environments. First
nature advantages relate to geography of the region while second nature advantages
relate to agglomeration economies that have advantages due to proximity of customers
and suppliers, technological externalities and better matching between employers and
employees (Charlot et al. 2015).
To account for other factors of the region that define knowledge output, we considered
GDP in region r for the years 2014 to 2017 such that β̂2 is the estimate of the effectiveness
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of other characteristics of the region as input to the KPF. To provide a uniform measure of
GDP, values were obtained at current market prices by million Euro, or other applicable
local currencies, and converted to units of per million US Dollars by dividing them
with purchasing power parities obtained using data provided by the OECD (2020b). We
calculated averages to receive one mean and uniform GDP value for the period 2014–2017.
Finally, to account for proximity effects in innovatory effort and other characteristics
of the region, we considered the spatial dependency of neighboring regions, assuming
that knowledge production is not only influenced by the inputs of the KPF of the region
itself but also by the inputs of the neighboring regions (Moreno et al. 2005, Charlot
et al. 2015). We consider spatial proximity and the related correlations of dependent
and independent variables as important given the role of user-producer interactions in
the development process of medical devices and the fragmented nature of the medical
device industry across geographical regions. Most importantly, we do not account for any
collaborating clusters across neighboring regions ex-ante in our data, so we need to allow
for knowledge and innovatory efforts to flow not only locally, but also across neighboring
regions. Accordingly, equation (2) can be extended to a spatial form as follows:
Kr = ρ̂ WK + β̂1Xr + θ̂1WX + β̂2Zr + θ̂2WZ + u (3)
u = λ̂ Wu + ϵr
Spatial lags of these variables are denoted by WK referring to knowledge outputs of the
neighboring regions, WX to funding mechanism received by the neighbor regions, WZ
to GDP of the neighbor regions, and Wu to unobserved environmental characteristics of
the neighbor regions. W is the weight matrix of the neighboring regions, for which we
defined a contiguity neighborhood matrix that assigns equal weight to all neighbors with
row-standardized values (Tosetti et al. 2018).
To assess the degree of spatial dependency across data reporting knowledge production
and research investments across regions, we first performed Moran’s I test for our specified
models (Lesage 2008, Elhorst 2010, Tosetti et al. 2018). We accounted for the spatial
dependency of both dependent and independent variables (Manski 1993): endogenous
interaction by knowledge output in the number of publications of neighboring regions (ρ),
exogenous interaction by inputs to the knowledge production function of the neighboring
regions (θ), and correlated effects by unobserved environment of the neighboring regions
(λ) (Elhorst 2010, Floach, Le Saout 2018). We followed a combined approach which
included parts of both bottom-up and top-down approaches for the selection of order
of spatial effects proposed (Elhorst 2010, Floach, Le Saout 2018). The purpose of the
approach is to account for spatial lags of the dependent variable and the error term
with robust Lagrange multiplier tests as a first step. As the second step, we specified a
Durbin model, which refers to the baseline model as described in (3), including lags of
independent variables and either ρ or λ. We then performed a likelihood ratio test,
comparing the model specifications with and without spatial autocorrelation of the
independent variables (θ) (Floach, Le Saout 2018). We only report relevant type of
spatial model specified in case where spatial effects were confirmed. All spatial tests and
analyses were performed using R version 4.0.2 (packages spdep, SDraw, spatialreg, rgeos)
[Supplement 5: Spatial Analysis and Results].
To estimate the elasticity of innovatory effort and other characteristics of the region,
we estimated models at the log scale (Moreno et al. 2005, Gumbau-Albert, Maudos
2009). Here, we needed to account for regions that do not report EU Horizon 2020 or
FP7 funding. Estimating models at the log scale is particularly challenging for values
of zero; we explicitly accounted for the lack of innovatory effort by including a dummy
variable (Battese 1997). In the appendix (Tables A.1 and A.2), we report another version
of the spatial KPF that excluded regions with zero innovatory effort in terms of public
funding received.
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3.5 Robustness analyses by input and output variables
To assess whether our results hold across different specifications, we performed additional
analyses accounting for non-public innovatory efforts to fund randomized clinical trials
that were part of the publications, the number of grants reported in the publications as
innovatory efforts, and observed healthcare system-related factors of the region besides
GDP.
To account for regional variation of innovatory effort from private sources, we mea-
sured receipts of private funding by capturing sponsorship of clinical trials by the industry.
We relied on the reporting of clinical trials in the publications captured in the MED-
LINE/PubMed database3 to link them with sponsorship information in ClinicalTrials.gov
(2021). In total, 1,242 clinical trials were reported in the publications. Accounting for
both lead and collaborative sponsors types that include industry, government, and non-
governmental agencies, we created a binary variable – “private funding.” For publications
corresponding to clinical trials with sponsorship from at least one industry sponsor, “one”
was assigned, otherwise “zero.” We counted the number of publications reporting private
funding by region.
To account for an alternative measure of innovatory effort from public funding sources,
we replaced the measure of innovatory effort by public funding with the number of
grants reported in the publications in the MEDLINE/PubMed dataset. We relied on
the reported element “GrantList” corresponding to those articles for which the authors
reported grant funding. It includes the name of the grant-funding agency along with
additional grant identifying details (NLM 2019b). These funding agencies are part of the
list maintained by the NLM and consist of US government health organizations, US non-
governmental funding organizations, and non-US funding agencies/organizations (NLM
2019b). We created a binary variable, “grant received,” coded as “one” for a publication
that reported at least one grant-funding agency and “zero” for no reported grant funding.
We grouped and aggregated the binary variable corresponding to the regions where the
published work was performed; thus, calculating the total number of publications that
received grants per region. This variable allows us to account for both public and non-
public grants as reported by the authors, while the EU Horizon 2020 and FP7 funding
volume allows us to account for public funds only. As this variable was collected only
from published studies, the grant variable does not account for funds acquired that did
not end up in publication.
We considered factors related to the regional health care environment to account for
additional confounding of the elasticities of public funding by other regional factors. For
cardiovascular care, potential confounders of public funding are the intensity of hospital
care in the region. In addition, there may be regional variations in unmet medical needs,
driving clinicians to develop new products and seek funding opportunities. In a subset
covering 422 regions of four countries (Germany, Italy, Switzerland, and Hungary), we
relied on a publicly available and recently extracted data set of hospital counts and life
expectancy at NUTS-level 3 (Rabbe et al. 2021). We first separately specified the baseline
model from equation (2) for these subsets of regions and then added hospital counts and
life expectancy to control for the regional health care system environment.
4 Results
4.1 Exploratory Spatial Data Analysis
Of the 1,394 regions in the 31 countries that we considered, 1,051 (75%) regions were
active in knowledge production as they had at least one cardiovascular device-related
publication between 2014 and 2017. Figures 1a and 1b provide an overview of the
exploratory spatial data analysis that demonstrates the regional variation in knowledge
output by number of publications in multiple western and southern European countries.
The figures depicting the remaining countries from our dataset are provided in the
appendix.
3In MEDLINE / Pubmed, an element named “DataBankList” provides ClinicalTrials.gov identifier
(i.e., NCT number) in cases when publication reports results of a clinical trial (NLM 2019b).
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Figure 1a: Publication Output for Cardiovascluar Medical Devices at Regional levels of
NUTS-3 in Europe: Netherlands, Belgium, Luxembourg, Germany, and Austria
Figure 1b: Publication Output for Cardiovascluar Medical Devices at Regional levels of
NUTS-3 in Europe: Switzerland, France, Portugal, Spain, Italy, and Malta
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Table 1a: The ten Most Active Regions in Cardiovascular Device Knowledge Output by
number of publications, 2014-2017
EU 2020 Horizon EU FP7 Funding
Region (NUTS-3) No. of Share of Total Funding Volume in Volume in
Publications Publications Million Euro Million Euro
Milano 1,730 2.58% 541 613
Westminster 1,674 2.50% 563 795
Paris 1,421 2.12% 2,558 3,168
Rome 1,380 2.06% 960 953
Madrid 1,195 1.78% 1,223 1,162
Barcelona 997 1.49% 1,023 1,005
Munich 911 1.36% 1,621 1,695
Groot-Amsterdam 905 1.35% 877 745
Groot-Rijnmond 828 1.24% 146 178
Berlin 812 1.21% 492 565
Note: Data on publications was obtained from the US NLM capturing 123,487 publications in the field
of cardiovascular devices, 2014-2017. A region is defined by NUTS level 3.
Table 1b: The ten Most Active Regions in Cardiovascular Device Knowledge Output by
number of publications per capita, 2014-2017
Publications Share of Total EU 2020 EU FP7
Region (NUTS-3) per Publications Horizon Funding Funding
Inhabitant per Inhabitant Volume in Euro Volume in Euro
Westminster 709 5.36% 2,382 3,366
Erlangen 316 2.39% 625 725
Heidelberg 263 1.99% 1,854 2,342
Basel-Stadt 169 1.28% 620 998
Camden and
City of London 152 1.15% 2,381 2,938
Jena 135 1.02% 460 481
Würzburg 134 1.01% 448 612
Freiburg im Breisgau 128 0.97% 254 69
El Hierro 121 0.92% 0 0
Regensburg 119 0.90% 220 424
Note: Data on publications was obtained from the US NLM capturing 123,487 publications in the field
of cardiovascular devices, 2014-2017. A region is defined by NUTS level 3.
The descriptive analysis suggests that knowledge production is highly distributed
across space (Table 1a and Table 1b). Even the region of Milano (Italy), producing the
highest number of publications (n = 1, 730), is responsible for only 2.58% of the total
publication output of Europe. For the absolute number of publications, Italy (Milano,
n = 1, 730; Roma, n = 1, 380), the United Kingdom (Westminster, n = 1, 674), France
(Paris, n = 1, 421), and Spain (Madrid, n = 1, 195) are the countries with the most active
regions. For the number of publications per capita, the UK (Westminster, n = 709;
Camden and City of London, n = 152), Germany (Erlangen, n = 316; Heidelberg,
n = 263), and Switzerland (Basel, n = 169) were found to be the countries with the most
active regions.
When we consider the country level, Germany (n = 11, 971), Italy (n = 10, 250),
the UK (n = 10, 079), France (n = 7, 302), and the Netherlands (n = 4, 941) are the
most active countries (Table 2). The geographical span across the European Economic
Area and adjacent countries further uncovers the regional level variation in knowledge
production of cardiovascular devices. For example, Germany had the highest number
of total publications (n = 11, 971) whereas only two regions (Munich, n = 911; Berlin,
n = 812) fell into the top ten highest publications producing regions, indicating that the
knowledge production activity of cardiovascular device research in Germany is widespread
rather than clustered in one or a few regions. On the contrary, Spain also has two
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Table 2: Inputs and Outputs of the Knowledge Production Function of Cardiovascular
Device Research by country, Europe 2014-2017
Total Publi- Publi- H2020 FP7 No. of
Country Active Publi- cations / cations / funding funding No. of private
Regions cations Region Capita (mill. e) (mill. e) grants funding
Germany 283 11,971 42 4,238 6,455 7,591 1,862 384
Italy 103 10,250 100 1,292 3,791 3,714 895 131
United Kingdom 164 10,079 61 2,728 5,846 8,020 6,122 191
France 86 7,302 85 644 4,997 5,832 545 174
Netherlands 37 4,941 134 702 3,431 3,847 1,188 158
Spain 53 4,920 93 582 4,100 3,468 422 129
Switzerland 21 2,673 127 503 1,408 2,500 341 64
Sweden 19 1,855 98 270 1,536 1,904 438 50
Denmark 10 1,813 181 292 1,151 1,095 222 55
Belgium 28 1,799 64 366 2,219 1,984 256 77
Poland 43 1,678 39 222 280 415 203 33
Greece 30 1,354 45 311 1,032 1,009 98 7
Austria 23 1,294 56 232 1,266 1,278 289 47
Portugal 20 824 41 109 701 540 71 4
Finland 17 758 45 176 1,013 904 361 20
Norway 17 756 44 160 1,007 789 113 22
Czech Republic 13 650 50 64 319 277 112 33
Ireland 8 508 64 68 501 640 118 4
Hungary 15 461 31 60 266 319 82 23
Romania 17 301 18 36 179 120 9 3
Croatia 11 167 15 38 64 71 1 0
Slovenia 8 147 18 35 236 157 11 1
Lithuania 5 99 20 15 56 46 0 3
Slovakia 6 97 16 15 83 68 22 1
Cyprus 1 71 71 8 212 100 32 0
Bulgaria 5 57 11 7 21 94 0 1
Latvia 2 51 26 8 67 44 8 7
Iceland 2 49 25 24 99 64 126 0
Estonia 2 28 14 7 93 93 2 2
Luxembourg 1 23 23 4 125 60 0 0
Malta 1 18 18 4 23 21 0 0
Note: Data on publications was obtained from the US NLM capturing 123,487 publications in the field
of cardiovascular devices, 2014-2017. A region is defined by NUTS level 3.
regions, Madrid (n = 1, 195) and Barcelona (n = 997), in the top ten absolute number
of publication output, but it lags behind many other countries in terms of the total
number of publications (n = 4, 920), suggesting clustering of research only in very active
centers. Table 2 further provides insights into country-level variations for the number
of active regions (i.e., producing at least 1 cardiovascular device related publication),
total publications, publications per region, publications per capita, total amount of EU
Horizon 2020 and FP7 funding by million Euro, total number of publications reporting
grants and private funding.
4.2 Estimates of the spatial Knowledge Production Function
The estimates of the (spatial) KPF models across the 1,051 regions reporting publication
output suggest that innovatory effort in the form of EU FP7 program funding between
2007 and 2013 increases knowledge production of cardiovascular devices from 2014 to
2017. The elasticity was 0.40 (p < 0.0001). It declined to 0.36 (p < 0.0001) when we
added country-fixed effects to the OLS specification and considered spatial dependency.
The EU Horizon 2020 program, that was active between 2014 and 2020, is positively
related to knowledge production of cardiovascular devices, with an elasticity of 0.13–0.17
(Table 3). For the EU Horizon 2020 program, our OLS-based estimate of the elasticity
was 0.17 (p < 0.0001). It declined to 0.13 (p < 0.001) when adding country-fixed effects
and accounting for spatial dependency.
The estimates of spillovers generated by neighboring regions were reported as the
indirect impacts of independent variables. Compared to the elasticity estimates in the
focal region, these were negative and small, both for receiving funding from FP7 and EU
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Table 3: Estimates of (Spatial) Knowledge Production Function by scientific publications
per capita, considering funding from EU FP7 and EU Horizon 2020 program as
innovatory effort – Inputs and outputs per capita (log-scale incl. zero)
OLS OLS SAR
EU FP7 program 0.40*** 0.36*** 0.36***
(0.04) (0.04) (0.04)
EU Horizon 2020 program 0.17*** 0.13** 0.13*
(0.04) (0.04) (0.04)
GDP 0.14*** 0.86*** 0.92***
(0.03) (0.13) (0.13)
Spillover FP7 - - -0.06
Spillover Horizon2020 - - -0.02
Spillover GDP - - -0.16
Total Impact FP7 - - 0.30
Total Impact Horizon2020 - - 0.11
Total Impact GDP - - 0.77
Observations 1051 1051 1051
Country Fixed Effects No Yes Yes
Adjusted R-squared 0.41 0.71 -
Moran’s I 0.02 -0.03 -
LM test: lags of Y 1.34 14.01** -
LM test: lags of e 0.76 2.43 -
ρ in SDEM (model with ρ and θ) - -0.15* -
ρ in constrained SDM (model with ρ only) - -0.20*** -
LR test: lags of Y and X (ρ and θ) - 50.17 -
Note: Data on cardiovascular device related publications in Europe from US NLM for the period 2014-
2017. Outcome variable in each regression is the log value of number of publications per capita. GDP:
gross domestic product; OLS: ordinary least squares; LM: Lagrange multiplier test; LR: likelihood ration
test; SAR: Spatial Durbin Model; Y : dependent variable; ϵ: error term; ρ: estimate of spatial effect by
dependent variable of the neighboring regions; θ: estimate of spatial effect by independent variables of
the neighbor regions; λ: estimate of spatial effects by error variables of the neighboring regions. p-values:
” p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001.
Horizon 2020 (Table 3, column 3). In the assessment of the spatial dependency, Moran’s
I was insignificant. However, the Lagrange multiplier tests and their robust counterparts
indicated possible interaction with knowledge outputs of neighboring regions (ρ). The
likelihood ratio tests in the second step between SDM (model with ρ and θ) and its
constrained form (model with ρ only) indicated the likelihood of only ρ to be present,
leading to specification of a spatial auto-regression (SAR) model, often termed as a spatial
lag model. Our estimate of the elasticity for the EU Horizon 2020 program remained at
0.13 (p < 0.01) in the SAR model. Considering that we capture fixed effects of all 31
countries to control for unobserved heterogeneity by the country, these elasticities are
sizeable. The elasticities of GDP estimate in the KPF were at a range of 0.14–0.92. Here,
we also find negative spillover of neighboring regions.
4.3 Estimates of the Knowledge Production Function controlling for additional inputs
Our estimates remain robust when considering additional inputs as confounders. As we
cannot rule out that higher knowledge production has led to better funding opportunities
of EU Horizon 2020 in the same period, only the estimates of EU FP7 can be validly
interpreted as a causal effect of innovatory effort on knowledge production. When we
additionally controlled for innovatory efforts by private funding for the clinical studies
present in our dataset (Table 4, column 1), the estimate of the elasticity of the EU
FP7 program reduced to 0.22 (p < 0.0001). These results demonstrate that even after
controlling for private funding received by clinical trial sponsorship in our dataset, the
effect of innovatory effort by EU FP7 program persists, although at a smaller magnitude.
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Table 4: Estimates of (Spatial) Knowledge Production Function by scientific publications
per capita, additional inputs by number of grants reported, private funding, health system
related factors – Inputs and outputs per capita (log-scale incl. zero)
4 countries Subgroup Analysis
OLS OLS OLS OLS
EU FP7 program 0.22*** - 0.34*** 0.34***
(0.04) - (0.06) (0.06)
EU Horizon 2020 program 0.08* - 0.13’ 0.14*
(0.04) - (0.06) (0.06)
Grants reported - 0.49*** - -
- (0.03) - -
Private Funding reported 0.49*** - - -
in clinical trials (0.06) - - -
GDP 0.54*** 0.97*** 1.26*** 1.20***
(0.11) (0.10) (0.20) (0.20)
Number of Hospitals - - - 0.55***
(0.12)
Life Expectancy - - - -3.54***
(4.88)
Observations 1051 1051 422 422
Country Fixed Effects Yes Yes Yes Yes
Adjusted R-squared 0.79 0.78 0.72 0.73
Moran’s I 0.00 0.00 0.00 0.00
LM test: lags of Y 8.3* 5.94 0.59 0.19
LM test: lags of e 0.04 0.02 0.03 0.00
Note: Data on cardiovascular device related publications in Europe from US NLM for the period 2014-
2017. Outcome variable in each regression is the log value of the number of publications per capita.
GDP: gross domestic product, OLS: ordinary least squares, LM: Lagrange multiplier test, LR: likelihood
ration test, SDM: Spatial Durbin Model; Y : dependent variable; ϵ: error term; ρ: estimate of spatial
effect by dependent variable of the neighboring regions; θ: estimate of spatial effect by independent
variables of the neighbor regions; λ: Estimate of spatial effects by error variables of the neighboring
regions. p-values: ’ p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001.
When we consider innovatory effort by the number of grants reported in the context
of cardiovascular device research (Table 4, column 2), we find a higher elasticity of 0.49
(p < 0.0001) as compared to our baseline models with the estimates of the EU FP7 and
Horizon 2020 measures of innovatory effort. Considering other regional characteristics
as additional inputs to the KPF with grants reported, we also find sizeable elasticity by
the regional GDP at 0.97 (p < 0.0001).
Accounting for additional factors of the region that relate to the health care envi-
ronment, we find similar estimates for the elasticities of the EU FP7 program in the
subgroup of regions in Germany, Italy, Switzerland, and Hungary (Table 4, columns
3–4). At baseline, the elasticity of the EU FP7 program was 0.34 (p < 0.0001). When
we controlled for the number of hospitals and life expectancy in the region, this estimate
of elasticity remained the same at 0.34 (p < 0.0001) for the EU FP7 program.
5 Discussion
Our estimates of the (spatial) KPF for cardiovascular publication output in the 1,051
active regions across 31 European and adjacent countries suggest that innovatory effort
via public funding substantially increases knowledge output. The estimates of the elas-
ticities ranged between 0.36 and 0.40 for the EU FP7 program. The underlying (and
considerable) heterogeneity in knowledge output that we documented is similar to the
uneven distribution of medical device usage and companies across Europe (MedTech
2020a, Tarricone et al. 2017). We also uncovered small but negative spillover in innovatory
effort and other characteristics of the neighboring regions on the regional knowledge
production. We also find positive associations of 0.13–0.17 for the EU Horizon 2020
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program, FP7’s successor, although they cannot be interpreted as a causal effect of
innovatory effort on knowledge production.
Contrary to our focus on cardiovascular devices that also has implications for patients
receiving innovation faster, previous studies have identified the role of innovatory efforts
by pooling input and output variables from several industries. The estimates of elasticities
of knowledge output in these studies ranged from 0.24 to 0.90 (Moreno et al. 2005,
Bottazzi, Peri 2003, Marrocu et al. 2013, Greunz 2003). Thus, our estimates of the
elasticities for the FP7 funding (0.36-0.40) are in middle of this range. In their factorial
analysis approach, Buesa et al. (2010) estimated the increase in the number of patents
by about 400–1,100 due to a regional environment consisting of economic and human
resources variables, about 200–270 due to innovatory firms’ internal R&D investment,
and about 25–80 due to the national economic environment. Some studies, such as
Gumbau-Albert, Maudos (2009) and Charlot et al. (2015), estimated R&D elasticities on
innovation outputs at 0.17–0.27 in Spanish and 0.26 in European regions, respectively;
the associations we find for the EU Horizon 2020 funding are aligned more closely to
this range (0.13–0.17). While these studies also capture innovatory effort by R&D
investments, measurement variables differed as they capture R&D investments mainly by
share of GDP or by internal R&D investment of the manufacturing firms. The relatively
high elasticity for estimates of the FP7 funding program (0.36-0.40) is possibly due to
a cumulative effect. Regions already receiving higher funding in the past had a higher
potential of producing research activities resulting in publications 2014-2017.
Our estimates confirm that the public funding brought to a region has a considerable
role in its innovation output in the medical device industry. For the medical device
industry-specific evidence, several regional clusters have been described on a descriptive
level, for example, the Medical Valley Nuremberg, Germany, or the Emilia Romagna
region in Italy (Klein et al. 2015, Valley 2020). However, few studies focus on quantitative
spatial analysis of the regions’ inputs and outputs related to the medical device industry.
The choice of innovation measure will also play an important role; analyzing elasticities
of public funding may not have similar effects for early intervention measure such as
patents that may predominantly rely on other funding sources such as venture capital.
However, recent industry reports suggest that the European medical device industry,
unlike that of the US, still heavily depends on public or semi-public grants (MedTech
2020b). In addition, even when private funding by the industry was controlled in case
of some publications reporting clinical trials, the estimates of the elasticities of the EU
FP7 program remained significant, albeit smaller.
The spatial spillovers of innovatory efforts on knowledge output are consistently ne-
gative, albeit on a small scale. It indicates that higher knowledge output in one region
resulting from its regional innovatory efforts indirectly and negatively influences the
knowledge output of neighboring regions. Innovative activity may withdraw innovative
activity from neighbor regions. The small to non-significant estimates of spillovers that
we detect are in line with previous evidence that uncovered the role of spatial proximity in
knowledge production. While Moreno et al. (2005) has demonstrated that spillovers are
significant for neighbors, as well as neighboring regions of the neighbors, Tappeiner et al.
(2008) showed that spatial correlation did not exist after controlling for all traditional
variables of the KPF. Finally, considering a semi-parametric approach, Charlot et al.
(2015) demonstrated that spillover effects are significant only for certain thresholds of
R&D expenditure.
The study had some limitations. First, our estimates of the elasticities of the KPF for
the innovatory effort captured by EU Horizon 2020 program may be subject to reverse
causality (Charlot et al. 2015). Most importantly, we cannot rule out that highly active
regions in terms of publication output successfully attract more R&D resources in the
form of grants or EU funding received. We aimed to accommodate this endogeneity
issue by considering innovatory efforts provided by the EU FP7 program. Considering
the estimates of the EU FP7 program, the threat of reverse causality is minimized as
the publications we captured were published after regions could acquire funding for this
program. In this way, we can rule out that the knowledge production we observe coincides
with obtaining research funds from the same publication output. However, the regions
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that received more funding for EU FP7 may also contain more human resources in the
academic activities that are more likely to attract public research funds in the first place.
Thus, for EU Horizon 2020, we cannot fully separate the effects of receiving funding
from the level of human resources dedicated to cardiovascular device research that are a
prerequisite to attract funds. Previous studies have considered this type of endogeneity
by capturing alumni representation in evaluation boards of funding institutions as an
instrument of receiving grants (Payne, Siow 2003). Estimates of the applied instrumental
variable regressions were similar in effect to those disregarding such type of endogeneity.
Such data was not readily available at the European level in the context of this study.
Second, our funding measure by the number of grants reported in one of our robustness
analyses may be subject to publication bias and bias if authors of one region would more
actively report their grants than authors in another region. It would lead to a problem
only in the case when there is a cultural practice in some regions for (not) reporting the
grants with the publications compared to others.
Third, as we focus only on funding mechanisms as innovatory effort and GDP as a
proxy for other regional characteristics, we cannot disentangle the relative elasticities
of other types of innovatory efforts (most importantly internal R&D investments and
human resources) and other regional economic or financial characteristics. For example,
Buesa et al. (2010) identified the relative importance of multiple input factors in the
KPF. Our primary aim was to evaluate the elasticities of public research funding relative
to other inputs, such as regional characteristics. However, as GDP is the single-most-
important indicator for economic activity of a region (OECD 2020a), one concern is that
adding additional regional characteristics leads to biases in the estimate of the elasticity
as these are intermediate variables on the path between GDP and publication output
and may cause collider-stratification biases. Our subgroup analyses that include health
system-related factors suggest that the estimates of the elasticities appear not strongly
biased when we exclude additional factors related to innovatory effort.
Fourth, we exclude the regions for which no publication output was documented
so that the estimated elasticities are conditional on some minimum degree of knowledge
production. In our data, we find that the 472 regions that did not publish a cardiovascular
device-related article received approximately 365 million Euro by EU FP7 funding com-
pared to about 47 billion Euro received by the regions with at least one publication, that
is about 1% of the total funding volume. Similarly, 588 million Euro in EU Horizon 2020
funding was received by these 472 regions, compared to 43 billion Euro in EU Horizon
2020 funding received by the regions with at least one publication – about 1% of the total
funding volume. As documented earlier, innovation systems in the regions not generating
knowledge output are likely very different from the other regions, such that our estimated
elasticities may not be transferrable to these regions (Charlot et al. 2015).
Fifth, funding by EU Horizon 2020 and EU FP7 programs is targeted for multidisci-
plinary research. Therefore, the possibility of knowledge spillover from other technologies
may moderate the effectiveness of the innovatory effort that we study for cardiovascular
device related research only.
Our study provides implications for R&D policymakers as well as the industry. Given
the high burden of disease in cardiovascular conditions, the global demand for R&D
in cardiovascular research is high (Komajda et al. 2013). When considering promoting
certain regions in their activity for knowledge production, most medical device innovators,
especially SMEs, have already been relying on public funding to innovate (MedTech
2020b). We show that targeting the levels of innovatory effort in the form of providing
funds does effectively increase knowledge production of a region and the underlying
networks. This finding is also relevant to justify related health and R&D policies or
non-profit initiatives that aim to improve the innovatory output of a region. While
our results point to a large geospatial heterogeneity in access to novel treatments from
medical device innovation, to what extent this innovatory effort leads to early adoption
of new and effective technologies in daily clinical use needs further investigation. With
such an analysis one could find out how much of the knowledge supported by public
funded in a region benefits that region. This way, policy makers could assess the spatial
rootedness of the knowledge production and thus, direct benefits to the region.
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Our approach in extracting publications for a particular medical field and assign
author affiliations may also be used to capture variation in knowledge production in
other medical areas where user-producer interactions are important, and patents may
not fully reflect the innovative activity beyond the first invention of the device. Location
of knowledge production may also be linked to other regional level health-related variables
such as mortality from cardiovascular diseases. This will allow studying, for example,
whether having an innovating expert in the region would also lead to quicker adoption of
health technology in routine care of cardiovascular patients and changes in the networks
of these experts.
6 Conclusion
Knowledge production of cardiovascular devices is largely spread across the regions of
Europe. Even the most active regions contribute relatively small shares of publications
that document innovation in cardiovascular devices. Receiving funding as a form of
innovatory effort is effective for generating new ideas and, subsequently, devices because
large parts of the industry are organized in small and medium enterprises, which rely
on the knowledge of clinicians and academics. Our results support the notion that the
regional innovation systems in Europe can be fostered by public research investments to
promote innovation in the medical device industry.
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Rabbe S, Möllenkamp M, Schreyoegg J, Blankart R, Torbica A, Pongiglione B
(2021) COMED datalibrary. Available: https://zenodo.org/record/4601476
Smith SW, Sfekas A (2013) How much do physician-entrepreneurs contribute to new
medical devices? Medical Care 51: 461–467. CrossRef.
Statistics Iceland (2019) Iceland gross domestic product. Statistics iceland
Stern AD (2017) Innovation under regulatory uncertainty: Evidence from medical
technology. Journal of Public Economics 145: 181–200. CrossRef.
Tappeiner G, Hauser C, Walde J (2008) Regional knowledge spillovers: Fact or artifact?
Research Policy 37: 861–874. CrossRef.
Tarricone R, Torbica A, Drummond M (2017) Challenges in the assessment of medical
devices: The MedtecHTA project. Health Economics 26 Suppl 1: 5–12. CrossRef.
Torvik VI (2015) MapAffil: A bibliographic tool for mapping author affiliation strings
to cities and their geocodes worldwide. D-Lib magazine : the magazine of the Digital
Library Forum 21. CrossRef.
Tosetti E, Santos R, Moscone F, Arbia G (2018) The spatial dimension of health systems.
Oxford research encyclopedias. CrossRef.
Usai S, Marrocu E, Paci R (2015) Networks, proximities, and interfirm knowledge
exchanges. International Regional Science Review 40: 377–404. CrossRef.
Valley M (2020) Medical Valley EMN e.V. Available: http://en.medical-valley-emn.de/-
contact
WHO (2017) Cardiovascular diseases (CVDs) fact sheets. Available: https://www.who.-
int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
Xu S, Avorn J, Kesselheim AS (2012) Origins of medical innovation: the case of coronary
artery stents. Circulation: Cardiovascular Quality and Outcomes 5: 743–9. CrossRef.
© 2021 by the authors. Licensee: REGION – The Journal of ERSA, European
Regional Science Association, Louvain-la-Neuve, Belgium. This article is distri-
buted under the terms and conditions of the Creative Commons Attribution, Non-Commercial
(CC BY NC) license (http://creativecommons.org/licenses/by-nc/4.0/).
REGION : Volume 8, Number 2, 2021
78 R. Vadia, K.E. Blankart
A Appendix:
Figure A.1: Publication Output for Cardiovascluar Medical Devices at Regional levels of
NUTS-3 in Europe: UK & Ireland
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Figure A.2: Publication Output for Cardiovascluar Medical Devices at Regional levels
of NUTS-3 in Europe: Bulgaria, Cyprus, Czech Republic, Estonia, Greece, Croatia,
Hungary, Lithuania, Latvia, Romania, Slovakia, Slovenia
Figure A.3: Publication Output for Cardiovascluar Medical Devices at Regional levels of
NUTS-3 in Europe: Iceland, Finland, Denmark, Sweden, Norway
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Table A.1: Estimates of (Spatial) Knowledge Production Function by scientific
publications per capita, excluding values with zero, considering funding from EU Horizon
2020 and EU FP7 program as innovatory effort – Inputs and outputs per capita (log-scale,
excluding values with zero)
OLS OLS SAR
EU FP7 program 0.41*** 0.38*** 0.37***
(0.04) (0.04) (0.04)
EU Horizon 2020 program 0.17*** 0.13** 0.13*
(0.04) (0.05) (0.04)
GDP 0.10** 0.86*** 0.92***
(0.04) (0.14) (0.13)
Spillover FP7 - - -0.07
Spillover Horizon2020 - - -0.03
Spillover GDP - - -0.19
Total Impact Horizon2020 - - 0.10
Total Impact FP7 - - 0.30
Total Impact GDP - - 0.75
Observations 914 914 914
Country Fixed Effects No Yes Yes
Adjusted R-squared 0.41 0.41 -
Moran’s I 0.02 -0.04 -
LM test: lags of Y 1.35 3.3807 -
LM test: lags of e 1.20 17.90*** -
ρ in SDEM (model with ρ and θ) - -0.16* -
ρ in constrained SDM (model with ρ only) - -0.24*** -
LR test of SDEM and SDM (ρ and θ) - 52.62 -
Note: Data on cardiovascular device related publications in Europe from US NLM for the period 2014-
2017. Outcome variable in each regression is the log value of number of publications per capita. GDP:
gross domestic product; OLS: ordinary least squares; LM: Lagrange multiplier test; LR: likelihood ration
test; SAR: Spatial Durbin Model; Y : dependent variable; ϵ: error term; ρ: estimate of spatial effect by
dependent variable of the neighboring regions; θ: estimate of spatial effect by independent variables of
the neighbor regions; λ: estimate of spatial effects by error variables of the neighboring regions. p-values:
” p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001.
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Table A.2: Estimates of (Spatial) Knowledge Production Function by scientific
publications per capita, additional inputs by number of grants reported, private funding,
health system related factors – Inputs and outputs per capita (log-scale incl. zero)
4 countries Subgroup Analysis
OLS OLS OLS OLS
EU FP7 program 0.29*** - 0.35*** 0.34***
(0.06) - (0.07) (0.07)
EU Horizon 2020 program 0.04 - 0.14 0.15*
(0.06) - (0.07) (0.07)
Grants reported - 0.55*** - -
(0.03)
Private Funding reported 0.57*** - - -
in clinical trials (0.05)
GDP 0.16 0.61*** 1.08*** 1.06***
(0.15) (0.13) (0.22) (0.22)
Number of Hospitals - - - 0.62***
(0.14)
Life Expectancy - - - -2.74
(5.22)
Observations 321 393 354 354
Country Fixed Effects Yes Yes Yes Yes
Adjusted R-squared 0.94 0.92 0.74 0.48
Moran’s I -0.01 -0.04 0.00 0.01
LM test: lags of Y 1.33 4.67 1.18 0.36
LM test: lags of e 0.04 1.49 0.01 0.04
Note: Data on cardiovascular device related publications in Europe from US NLM for the period 2014-
2017. Outcome variable in each regression is the log value of the number of publications per capita.
GDP: gross domestic product, OLS: ordinary least squares, LM: Lagrange multiplier test, LR: likelihood
ration test, SDM: Spatial Durbin Model; Y : dependent variable; ϵ: error term; ρ: estimate of spatial
effect by dependent variable of the neighboring regions; θ: estimate of spatial effect by independent
variables of the neighbor regions; λ: Estimate of spatial effects by error variables of the neighboring
regions. p-values: ” p < 0.05, * p < 0.01, ** p < 0.001, *** p < 0.0001.
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